Combining Radiation Therapy with ALK Inhibitors in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer (NSCLC): A Clinical and Preclinical Overview

類似資料

• An Exploration into the Origins and Pathogenesis of Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase (ALK)-Positive
  著者:: Suzanne D. Turner
  出版事項: (2017-10-01)
• An Exploration into the Origins and Pathogenesis of Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase (ALK)-Positive
  著者:: Turner, Suzanne D.
  出版事項: (2017)
• Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer
  著者:: Iwama, Eiji, 等
  出版事項: (2014)
• Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
  著者:: Alam, Muhammad Wasi, 等
  出版事項: (2019)
• A Patient with Anaplastic Lymphoma Kinase (ALK) FISH Positive NSCLC with Development of Leptomeningeal Carcinomatosis while on Targeted Treatment with Crizotinib
  著者:: Riess, Jonathan W., 等
  出版事項: (2013)